| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
12,577 |
10,418 |
$905K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
10,926 |
10,060 |
$873K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
6,061 |
5,529 |
$582K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,229 |
5,467 |
$544K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,490 |
5,568 |
$492K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
12,102 |
10,255 |
$460K |
| S9083 |
Global fee urgent care centers |
2,438 |
1,876 |
$185K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
6,049 |
5,431 |
$150K |
| 87428 |
|
2,822 |
2,570 |
$80K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,263 |
2,049 |
$68K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
9,889 |
8,302 |
$60K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,571 |
1,418 |
$44K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
490 |
428 |
$34K |
| 99452 |
|
399 |
378 |
$19K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
447 |
396 |
$16K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
195 |
183 |
$15K |
| 36415 |
Collection of venous blood by venipuncture |
495 |
432 |
$11K |
| 0071A |
|
133 |
122 |
$5K |
| 0004A |
|
143 |
123 |
$4K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
524 |
493 |
$4K |
| 0072A |
|
121 |
110 |
$4K |
| 87634 |
|
127 |
110 |
$2K |
| 0064A |
|
79 |
69 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
84 |
78 |
$2K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
105 |
88 |
$2K |
| 81003 |
|
933 |
822 |
$1K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
41 |
38 |
$1K |
| 81025 |
|
409 |
353 |
$1K |
| 71046 |
Radiologic examination, chest; 2 views |
92 |
85 |
$1K |
| 0124A |
|
30 |
27 |
$1K |
| 0002A |
|
29 |
28 |
$918.40 |
| 0012A |
|
30 |
29 |
$915.58 |
| 99215 |
Prolong outpt/office vis |
16 |
14 |
$775.18 |
| 80053 |
Comprehensive metabolic panel |
185 |
156 |
$733.15 |
| 99173 |
|
115 |
105 |
$722.24 |
| 99441 |
|
17 |
14 |
$601.39 |
| 0011A |
|
17 |
15 |
$583.03 |
| 93000 |
|
65 |
61 |
$545.37 |
| 0001A |
|
22 |
20 |
$480.42 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
162 |
134 |
$467.82 |
| 90674 |
|
48 |
42 |
$398.20 |
| 90688 |
|
20 |
15 |
$108.34 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
26 |
23 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
24 |
21 |
$0.00 |